Published in Telemedicine Law Weekly, January 13th, 2007
This trend article is an immediate alert from NewsRx to identify the most recent news developments at Predix Pharmaceuticals.
Report 1: Predix Pharmaceuticals announced that PRX-03140, its highly selective, proprietary serotonin 4 (5-HT4) receptor agonist, showed the desired alterations in brain wave activity in patients with mild-to-moderate Alzheimer disease and was well-tolerated in a recently completed 14-day phase Ib clinical trial.
In parallel with these clinical development efforts, several positive studies of PRX-03140 in key preclinical models for memory, cognition, and...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Telemedicine Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.